In vitro evaluation of effects of sustained anti-TNF release from MPEG-PCL-MPEG and PCL microspheres on human rheumatoid arthritis synoviocytes

Abstract

Anti-tumor necrosis factor α (TNFα) drugs such as etanercept (ETN) have been mostly used in systemic treatment of rheumatoid arthritis. To eliminate the side effects in long-term treatments and to achieve a local sustained anti-inflammatory effect, a controlled drug delivery system is needed for anti-TNFα drugs. This study aims to develop novel injectable microcarriers of ETN that can provide long-term controlled release of this protein drug upon intra-articular application. In this study, poly(ε-caprolactone) (PCL) and its copolymer with poly(ethylene glycol), methoxypoly(ethylene glycol)-poly(ε-caprolactone)-methoxypoly(ethylene glycol) microspheres (MPEG-PCL-MPEG) were compared for their prospective success in rheumatoid arthritis treatment. Microspheres with smooth surface of a mean particle diameter of approximately 5 μm were prepared with both polymers. MPEG-PCL-MPEG microspheres had higher encapsulation efficiency than PCL microspheres. The activity of encapsulated ETN within MPEG-PCL-MPEG microspheres also retained while 90% of the activity of ETN within PCL microspheres could retain during 90-day release. MPEG-PCL-MPEG microspheres showed faster ETN release compared to PCL microspheres in various release media. Cumulative amounts of ETN released from both types of microspheres were significantly lower in cell culture medium and in synovial fluids than in phosphate buffered saline. This was mainly due to protein adsorption onto microspheres. Hydrophilic MPEG segment enhanced ETN release while preventing protein adsorption on microspheres compared to PCL. Sustained ETN release from microspheres resulted with a significant decrease in pro-inflammatory cytokines (TNFα, IFNγ, IL-6, IL-17) and MMP levels (MMP-3, MMP-13), while conserving viability of fibroblast-like synoviocytes compared to the free drug. Results suggest that MPEG-PCL-MPEG is a potential copolymer of PCL that can be used in development of biomedical materials for effective local treatment purposes in chronic inflammatory arthritis owing to enhanced hydrophilicity. Yet, PCL microspheres are also promising systems having good compatibility to synoviocytes and would be especially the choice for treatment approach requiring longer term and slower release.

Keywords

Etanercept methoxy poly(ethylene glycol)–poly(ε-caprolactone)–methoxy poly(ethylene glycol)microspheres intra-articular delivery rheumatoid arthritis anti-tumor necrosis factor α drugs amphiphilic triblock copolymer

Get full access to this article

View all access options for this article.

References

Lipsky

Rheumatoid arthritis. In: Fauci

Langford

(eds). Harrison's rheumatology, 2nd ed. New York: McGraw-Hill, 2010, pp. 82–99.

Noss

Brenner

. The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis. Immunol Rev 2008; 223: 252–270.

Feldmann

. Translating molecular insights in autoimmunity into effective therapy. Annu Rev Immunol 2009; 27: 1–27.

Feldmann

. Pathogenesis of arthritis: Recent research progress. Nat Immunol 2001; 2: 771–773.

MacNaul

Chartrain

Lark

. Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts. Synergistic effects of interleukin-1 and tumor necrosis factor-alpha on stromelysin expression. J Biol Chem 1990; 265: 17238–17245.

Agarwal

Misra

Aggarwal

. Synovial fluid RANKL and matrix metalloproteinase levels in enthesitis related arthritis subtype of juvenile idiopathic arthritis. Rheumatol Int 2009; 29: 907–911.

Frank

Peters

Wehmeyer

. Regulation of matrixmetalloproteinase-3 and matrixmetalloproteinase-13 by SUMO-2/3 through the transcription factor NF-kappaB. Ann Rheum Dis 2013; 72: 1874–1881.

Gattorno

Gerloni

Morando

. Synovial membrane expression of matrix metalloproteinases and tissue inhibitor 1 in juvenile idiopathic arthritides. J Rheumatol 2002; 29: 1774–1779.

Lubberts

. Th17 cytokines and arthritis. Semin Immunopathol 2010; 32: 43–53.

10.

Lubberts

Koenders

van den Berg

. The role of T-cell interleukin-17 in conducting destructive arthritis: Lessons from animal models. Arthritis Res Ther 2005; 7: 29–37.

11.

Roeleveld

van Nieuwenhuijze

van den Berg

. The Th17 pathway as a therapeutic target in rheumatoid arthritis and other autoimmune and inflammatory disorders. BioDrugs 2013; 27: 439–452.

12.

Kirkham

Lassere

Edmonds

. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: A two-year prospective study (the DAMAGE study cohort). Arthritis Rheum 2006; 54: 1122–1131.

13.

Kotake

Udagawa

Takahashi

. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999; 103: 1345–1352.

14.

Rodeghero

Cao

Olalekan

. Location of CD4+ T cell priming regulates the differentiation of Th1 and Th17 cells and their contribution to arthritis. J Immunol 2013; 190: 5423–5435.

15.

Fossiez

Djossou

Chomarat

. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996; 183: 2593–2603.

16.

Jovanovic

Di Battista

Martel-Pelletier

. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol 1998; 160: 3513–3521.

17.

Smolen

Aletaha

Koeller

. New therapies for treatment of rheumatoid arthritis. Lancet 2007; 370: 1861–1874.

18.

Zalevsky

Secher

Ezhevsky

. Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. J Immunol 2007; 179: 1872–1883.

19.

Gomez-Reino

Carmona

Valverde

. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report. Arthritis Rheum 2003; 48: 2122–2127.

20.

Magnano

Robinson

Genovese

. Demyelination and inhibition of tumor necrosis factor (TNF). Clin Exp Rheumatol 2004; 22: S134–140.

21.

Adriaansen

Khoury

de Cortie

. Reduction of arthritis following intra-articular administration of an adeno-associated virus serotype 5 expressing a disease-inducible TNF-blocking agent. Ann Rheum Dis 2007; 66: 1143–1150.

22.

Bliddal

Terslev

Qvistgaard

. A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis. Scand J Rheumatol 2006; 35: 341–345.

23.

Bliddal

Terslev

Qvistgaard

. Safety of intra-articular injection of etanercept in small-joint arthritis: An uncontrolled, pilot-study with independent imaging assessment. Joint Bone Spine 2006; 73: 714–717.

24.

Boesen

Jensen

. Clinical outcome and imaging changes after intraarticular (IA) application of etanercept or methylprednisolone in rheumatoid arthritis: Magnetic resonance imaging and ultrasound-Doppler show no effect of IA injections in the wrist after 4 weeks. J Rheumatol 2008; 35: 584–591.

25.

Kim

Pack

Microspheres for drug delivery. In: Ferrari

Lee

(eds). BioMEMS and biomedical nanotechnology, New York: Springer, 2006, pp. 19–50.

26.

Woodruff

Dietmar

. The return of a forgotten polymer: Polycaprolactone in the 21st century. Prog Polym Sci 2010; 35: 1217–1256.

27.

Sinha

Bansal

Kaushik

. Poly-epsilon-caprolactone microspheres and nanospheres: An overview. Int J Pharm 2004; 278: 1–23.

28.

Dash

Konkimalla

. Polymeric modification and its implication in drug delivery: Poly-epsilon-caprolactone (PCL) as a model polymer. Mol Pharm 2012; 9: 2365–2379.

29.

Wei

Gong

Gou

. Biodegradable poly(epsilon-caprolactone)-poly(ethylene glycol) copolymers as drug delivery system. Int J Pharm 2009; 381: 1–18.

30.

Lemmouchi

Perry

Amass

. Novel synthesis of biodegradable amphiphilic linear and star block copolymers based on poly(epsilon-caprolactone) and poly(ethylene glycol). J Polym Sci Pol Chem 2007; 45: 3975–3985.

31.

Zhou

Deng

Yang

. Biodegradable poly(epsilon-caprolactone)-poly(ethylene glycol) block copolymers: Characterization and their use as drug carriers for a controlled delivery system. Biomaterials 2003; 24: 3563–3570.

32.

Jia

Gou

. Preparation of biodegradable polycaprolactone/poly (ethylene glycol)/polycaprolactone (PCEC) nanoparticles. Drug Deliv 2008; 15: 409–416.

33.

Gou

Dai

. Preparation of mannan modified anionic PCL-PEG-PCL nanoparticles at one-step for bFGF antigen delivery to improve humoral immunity. Colloids Surf B Biointerfaces 2008; 64: 135–139.

34.

Gou

Dai

. Basic fibroblast growth factor loaded biodegradable PCL-PEG-PCL copolymeric nanoparticles: Preparation, in vitro release and immunogenicity study. J Nanosci Nanotechnol 2008; 8: 2357–2361.

35.

Erdemli

. Development of novel controlled release formulations of anti-TNF for rheumatoid arthritis and modeling of release behaviors. Engineering Sciences, Ankara: Middle East Technical University, 2013.

36.

Erdemli

Usanmaz

Keskin

. Characteristics and release profiles of MPEG-PCL-MPEG microspheres containing immunoglobulin G. Colloids Surf B Biointerfaces 2014; 117: 487–496.

37.

Wong

Wang

. In vitro sustained release of human immunoglobulin G from biodegradable microspheres. Ind Eng Chem Res 2001; 40: 933–948.

38.

Cho

Lee

Park

. Effect of graft copolymer composition on the compatibility of biodegradable PCL/PCL-g-PEG blend. Polym-Korea 2009; 33: 248–253.

39.

Siepmann

. Mathematical modeling of drug delivery. Int J Pharm 2008; 364: 328–343.

40.

Fickert

Fiedler

Brenner

. Identification, quantification and isolation of mesenchymal progenitor cells from osteoarthritic synovium by fluorescence automated cell sorting. Osteoarthrit Cartil 2003; 11: 790–800.

41.

Butoescu

Jordan

Doelker

. Intra-articular drug delivery systems for the treatment of rheumatic diseases: A review of the factors influencing their performance. Eur J Pharm Biopharm 2009; 73: 205–218.

42.

Kaur

Harikumar

. Controlled drug delivery approaches for rheumatoid arthritis. J Appl Pharm Sci 2012; 2: 21–32.

43.

Larsen

Ostergaard

Larsen

. Intra-articular depot formulation principles: role in the management of postoperative pain and arthritic disorders. J Pharm Sci 2008; 97: 4622–4654.

44.

Mumper

Jay

. Poly(L-lactic acid) microspheres containing neutron-activatable holmium-165: A study of the physical characteristics of microspheres before and after irradiation in a nuclear reactor. Pharm Res 1992; 9: 149–154.

45.

James

. Injectable dispersed systems: Formulation, processing, and performance, Florida, USA: Taylor & Francis Group, LLC, 2005.

46.

Vonarbourg

Passirani

Saulnier

. Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials 2006; 27: 4356–4373.

47.

Paillard-Giteau

Tran

Thomas

. Effect of various additives and polymers on lysozyme release from PLGA microspheres prepared by an s/o/w emulsion technique. Eur J Pharm Biopharm 2010; 75: 128–136.

48.

Muller

Voros

Csucs

. Surface modification of PLGA microspheres. J Biomed Mater Res Part A 2003; 66A: 55–61.

49.

Oates

Krause

Jones

. Rheopexy of synovial fluid and protein aggregation. J R Soc Interface 2006; 3: 167–174.

50.

Lipowitz

Synovial fluid. In: Newton

Nunamaker

(eds). Textbook of small animal orthopaedics, New York: International Veterinary Information Service, 1985, pp. 1015–1028.

51.

Rinaudo

Rozand

Mathieu

. Role of different pre-treatments on composition and rheology of synovial fluids. Polymers 2009; 1: 16–34.

52.

Aly

. Intra-articular drug delivery: A fast growing approach. Recent Pat Drug Deliv Formul 2008; 2: 231–237.

53.

Kim

Bae

. Albumin loaded microsphere of amphiphilic poly(ethylene glycol)/ poly(alpha-ester) multiblock copolymer. Eur J Pharm Sci 2004; 23: 245–251.

54.

Xie

. Preparation and evaluation of PEG-PCL nanoparticles for local tetradrine delivery. Int J Pharm 2009; 379: 158–166.

55.

Pean

Boury

Venier-Julienne

. Why does PEG 400 co-encapsulation improve NGF stability and release from PLGA biodegradable microspheres? Pharm Res 1999; 16: 1294–1299.

56.

Verma

Chanchal

Maitra

. Co-polymeric hydrophilic nanospheres for drug delivery: release kinetics, and cellular uptake. Indian J Exp Biol 2010; 48: 1043–1052.

57.

Kaymakcalan

Kalghatgi

Xiong

. F.76 Differential TNF-neutralizing potencies of adalimumab, etanercept and infliximab. Clin Immunol 2006; 119: S77–S78.

58.

Mohammed

Smookler

Khokha Ann

. Metalloproteinases, inflammation, and rheumatoid arthritis. Rheum Dis 2003; 62(Suppl II): ii43–ii47.